

亞東紀念醫院人體試驗審議委員會

Research Ethics Review Committee

Far Eastern Memorial Hospital

21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City 220, Taiwan (R.O.C.)

Tel : (02)7728-2152 Fax : (02)7728-2152

Email : irb@mail.femh.org.tw

個案報告發表許可書

西元二〇二〇年四月一日

案件編號：

個案報告名稱： 個案報告： 肝臟碰撞性腫瘤-原發性肝癌-神經內分泌腫瘤

作者：

受試者說明及同意書版本： 免除受試者說明及同意書

上述個案報告已經過本院人體試驗審議委員會審查，同意發表。

主任委員



Permission of Case Report Publication Far Eastern Memorial Hospital

Date: April 1, 2020

FEMH No.: 109054-C

Case Report Title: Liver collision tumor — primary hepatocellular carcinoma -
neuroendocrine carcinoma: A case report

Author:

Informed Consent Form: Waiver

Above case report has been approved for publication by the Research Ethics Review Committee of the Far Eastern Memorial Hospital.

亞東紀念醫院人體試驗審議委員會

Research Ethics Review Committee

Far Eastern Memorial Hospital

21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City 22060, Taiwan (R.O.C.)

Tel : (02)7728-2152 Fax : (02)7728-1592

Email : irb@mail.femh.org.tw

人體試驗/研究許可書

西元二〇二〇年二月一日

案件編號：

計畫名稱：MAPK 與 Hedgehog 分子之交互作用機制及臨床應用於肝纖維化及肝癌

計畫主持人：

共/協同主持人：

研究成員：

計畫書版本：version:4, date:20200130

受試者說明及同意書版本：免除受試者說明及同意書

中文摘要：version.1, date:20191214

英文摘要：version.1, date:20191214

個案報告表：Eversion.1, date.20200130

試驗期間：2020年3月1日至2023年7月31日

試驗人數：150

追蹤審查頻率：一年

上述計劃已於本院人體試驗審議委員會審查，同意人體試驗/研究進行。

本委員會的運作符合優良臨床試驗準則及政府相關法律規章。

本臨床試驗/研究許可書之有效期限自二〇二〇年三月一日至二〇二一年二月二十八日。(請於有效期限到期二個月前繳交持續審查報告以利本會進行審查)

主任委員

**Permission of Clinical Trial
Far Eastern Memorial Hospital**



Date: February 1, 2020

FEMH-IRB No.:

Protocol Title: The crosstalk mechanism and clinical application for MAPK and Hedgehog molecules in hepatic fibrosis and tumors

Principal investigator:

Co- investigator:

Research Associate:

Protocol Version: version:4, date:20200130

Informed Consent Form: Waiver

Chinese Synopsis: version.1, date:20191214

English Synopsis: version.1, date:20191214

eCase report form: Eversion.1, date.20200130

Trial period: March 1, 2020 to July 31, 2023

P10003-02-002-06- 2020-01-05





Number of subjects: 150

Continuing review frequency: One year

Above study has been approved by the Research Ethics Review Committee of the Far Eastern Memorial Hospital.

The committee is organized under, and operates in accordance with, the Good Clinical Practice guidelines and governmental laws and regulations.

The duration of this approval since March 1, 2020 to February 28, 2021.

(The investigator is required to apply for a continuing review not less than two months prior to the approval expiration date.)

Shu-Wen Chang M.D., Professor of Ophthalmology

Chairman

Research Ethics Review Committee